Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network

 Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider
                                   Network

Preferred Provider Organization network has more than 10 million covered
lives; one-in-five Americans now covered for the Rosetta Cancer Origin Test™

PR Newswire

PHILADELPHIA and REHOVOT, Israel, June 7, 2013

PHILADELPHIA and REHOVOT, Israel, June 7, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces that the Company has executed
a credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) of
Chula Vista, Calif., for the Rosetta Cancer Origin Test. TRPN is one of the
largest supplemental Preferred Provider Organizations (PPO) in the U.S.,
providing healthcare benefits to more than 10 million members nationwide.

"This is the second credentialing agreement executed between Rosetta and a
U.S. PPO. Together with Medicare reimbursement, the total number of covered
lives and for which the Rosetta Cancer Origin Test could be adjudicated as
'in-network' now exceeds 61 million, which means that one-in-five Americans
are covered for the Rosetta Cancer Origin Test," said Kenneth A. Berlin
President and Chief Executive Officer of Rosetta Genomics. "We continue to
pursue additional agreements with other PPOs as they provide faster payment
while maintaining acceptable levels of reimbursement, and also reduce costs
incurred through appealing denials. This has become increasingly important to
our company as we continue to see a growing number of samples being processed
and billed by our CLIA lab."

"This agreement comes at a good time for Rosetta as it follows on our strong
presence at ASCO 2013, where we significantly enhanced the awareness of the
Cancer Origin Test among an audience of the world's leading oncologists and
researchers. In addition, positive trends in billable and processed samples
for the Cancer Origin Test have led us to begin expansion of our sales
territories from 5 to 12. The credentialing agreement with TRPN further
enhances our ability to gain traction in the market and to further increase
access of this test to patients with a CUP diagnosis.

"With more than 200,000 patients per year presenting with Cancer of Unknown or
Uncertain Primary (CUP) or who would otherwise benefit from this test, this
expanding coverage reflects the importance of determining the tumor origin in
hard-to-diagnose metastatic cancers and CUP. This is particularly important
as new, molecularly-targeted cancer treatments are developed. We believe the
Rosetta Cancer Origin Test^™ can help physicians to accurately diagnose tumor
origin in order to optimize treatment. The availability and accuracy of our
Cancer Origin Test underscores why the uncertainty of CUP is no longer
acceptable," Mr. Berlin added.

A PPO is a managed care organization of medical doctors, hospitals and other
health care providers that has covenanted with an insurer or a third-party
administrator to provide health care at reduced rates to the insurer's or
administrator's clients. Credentialing is a process whereby provider
organizations such as physicians, care facilities and ancillary providers
(including testing service providers such as Rosetta Genomics') contract
directly with the PPO.

About Three Rivers Provider Network
Three Rivers Provider Network was founded in 1996 as a company that was
contracted to provide services for several major auto clients. At that time,
its clients needed to access a network that would grant PPO-type discounts
without incurring balance billing risks for their members. Over time, given
superior results and high levels of satisfaction of service, TRPN was prompted
by other companies that focused on group health and workers' compensation to
perform similar type services for them. TRPN contracts were uniquely designed
for group health, workers' compensation and auto liability claims expanding
existing coverage and significantly reducing out-of-network expense.

Since that time, TRPN has evolved into the largest and fastest-growing
proprietary PPO network in the U.S. The TRPN network is now comprised of more
than 600,000 total providers, including more than 5,000 hospitals and 70,000
ancillary facilities. Through its clients, approximately 10 million lives now
have access to the TRPN PPO network.

About Rosetta Cancer Testing Services (formerly the miRview^® product line)
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing
services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can
accurately identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma
Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The
Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung
cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™
accurately classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from
the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™
and 226,000 patients from the Rosetta Lung Cancer Test™. The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through distributors
around the world. For more information, please visit www.rosettagenomics.com.
Parties interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000, Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's cancer testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, Rosetta's Cancer of Origin
Test, improving the ability of physicians to accurately diagnose CUP, the
growth in number of samples being processed and billed at Rosetta's CLIA lab,
Rosetta's development or commercialization of molecular diagnostics, the
market acceptance of Rosetta's cancer testing services,particularly the
Rosetta Cancer Origin Test™, Rosetta's capitalization of its microRNA
platform, Rosetta's patent positionand Rosetta's development of personalized
medicine products and servicesconstitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

SOURCE Rosetta Genomics

Website: http://www.rosettagenomics.com
 
Press spacebar to pause and continue. Press esc to stop.